What is morphea (localized scleroderma)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Morphea (Localized Scleroderma)

Morphea, also called localized scleroderma, is a chronic autoimmune fibrosing disorder that causes skin thickening and hardening due to excessive collagen deposition, primarily affecting the skin and underlying tissues (subcutaneous fat, fascia, muscle, and bone) but—unlike systemic sclerosis—does not involve internal organs. 1, 2

Disease Classification and Subtypes

Morphea encompasses five distinct clinical subtypes that determine prognosis and treatment approach 1:

  • Circumscribed morphea: Limited, superficial plaques that are usually of cosmetic concern only and typically resolve within 3 years 3, 4
  • Linear scleroderma: Linear sclerotic plaques that can be severely disfiguring, especially when affecting the face ("en coup de sabre") or extremities, with risk of functional disability 1, 3
  • Generalized morphea: Extensive involvement affecting large body surface areas 1
  • Pansclerotic morphea: The most severe form involving deep tissues 1
  • Mixed subtype: Combination of two or more subtypes 1

Epidemiology

  • Morphea is 10 times more prevalent than systemic sclerosis 4
  • Juvenile localized scleroderma has an incidence of approximately 3.4 cases per million children per year 5
  • Female to male ratio is 2.4:1 with mean age of onset at 7.3 years in children 5
  • Adult-onset occurs in about 32% of cases and shows a more aggressive course with increased risk of systemic involvement 6

Clinical Presentation

The disease manifests with characteristic features 3, 5:

  • Sclerotic plaques with skin induration and thickening
  • Hyperpigmentation or hypopigmentation of affected areas
  • Active inflammatory lesions during the disease's active phase
  • Alopecia when scalp is involved
  • Depressed, fibrotic lesions that can cause significant cosmetic disfigurement
  • Deep tissue involvement in morphea profunda affecting dermis, subcutaneous tissue, fascia, and muscle 7

Pathophysiology

The exact pathogenesis remains unknown, but the disease process involves 2:

  • Immunologically triggered release of pro-inflammatory cytokines in genetically predisposed individuals
  • Profound dysregulation of connective tissue metabolism
  • Excessive collagen deposition leading to fibrosis
  • No specific serological markers are available for diagnosis 2

Critical Distinction from Systemic Sclerosis

The defining characteristic of morphea is that manifestations are confined to the skin and subdermal tissues and, with rare exceptions, do not affect internal organs—this distinguishes it from systemic sclerosis. 1 Therefore, in the absence of symptoms, examinations to detect systemic involvement are purposeless 4.

Prognosis

  • Superficial forms generally have good prognosis and resolve within 3 years 4
  • Linear forms, especially in children affecting the face or extremities, can be severe and irreversibly disabling 8
  • The significance depends on extent of lesions, potential for functional disability or cosmetic disfigurement, and presence of extracutaneous manifestations 8

Common Pitfall

A critical diagnostic pitfall is mistaking morphea for other conditions such as lichen sclerosus, especially in extragenital sites 3. Skin biopsy from the most active sclerotic area is crucial when diagnostic uncertainty exists or atypical features are present 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Localized scleroderma.

Dermatologic therapy, 2012

Guideline

Diagnosis and Management of Linear Morphea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Localized scleroderma (morphea)].

Presse medicale (Paris, France : 1983), 2006

Guideline

Parry-Romberg Syndrome and Localized Cranial Scleroderma Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Solitary Morphea Profunda: A Case Report.

Mymensingh medical journal : MMJ, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.